Cancer deaths in the United States fell 2.2% from 2016 to 2017 – the largest single-year drop ever recorded – fueled in large part by progress against lung cancer, the leading cause of cancer death, the American Cancer Society (ACS) reported.

Danish drugmaker Novo Nordisk is aiming for a big slice of the multibillion-dollar diabetes market with a new pill approved by U.S. authorities that caters for patients with an aversion to needles.

People who start fasting every other day may lose more weight than they would if they stuck to their usual eating habits, a small study suggests.

Lilly’s diabetes drug Trulicity hit the mark in a late-stage trial showing higher doses of the medication significantly reduced A1C from baseline versus the product’s approved once-weekly usage.

Danish drugmaker Novo Nordisk beat first-quarter 2019 operating profit forecasts, helped by higher sales of the company’s biggest new drug hope, a treatment for type 2 diabetes.

Gelesis announced that the United States Food and Drug Administration cleared the biotechnology company’s lead product candidate Plenity (Gelesis100) as an aid in weight management in adults with a Body Mass Index (BMI) of 25–40 kg/m2, when used in conjunction with diet and exercise.

A 2017 study found that more than 700 million adults and children worldwide are obese, calling it a “rising pandemic.”

Tivity Health Inc. said the company would acquire Nutrisystem Inc. in a cash-and-stock deal that values the weight management product developer at $1.4 billion.

Researchers at Flinders University in Australia – working with mice – removed a single gene known as RCAN1 and then fed them a variety of diets, including a high-fat diet. The mice did not gain weight, even after dramatically overeating high-fat foods over several weeks.

Alkermes Plc’s schizophrenia drug ALKS 3831 met the main goal of keeping in check a common side effect of antipsychotic medicines – weight gain – taking the company one step closer to a marketing approval for the experimental treatment.